
Haley B. Naik, M.D., on why new HS guidelines recommend against radiotherapy for HS in children and teens
New guidelines for care of hidradenitis suppurativa advise against radiotherapy for children and adolescents, citing its long-term risks and safer treatment options.
New guidelines of care for
The radiotherapy recommendation is the guidelines' only recommendation against an intervention issued as a good practice statement. The work group uses that designation when the supporting evidence is considerable but indirect and the certainty about an intervention's impact is high. The guidelines treat good practice statements as strong recommendations.
Direct evidence on radiotherapy for HS in children is “sparse,” according to the guidelines. But radiotherapy carries well-established long-term risks in children and adolescents, including malignancy, infertility, tissue fibrosis, growth abnormalities and endocrine dysfunction, and safer options for treating HS in young patients now exist.
Naik said radiotherapy is still used in some clinical practices, including for pediatric and adolescent HS. "We do have pretty good therapies now for management of HS," she said, and the work group concluded that the long-term risks of radiotherapy outweigh its benefits in that age group.
The guidelines do not make a recommendation for or against radiotherapy in adults. They describe the overall evidence as insufficient, drawing on four case series covering 109 patients that used varied radiotherapy approaches and doses and carried moderate to high risk of bias. Naik said there may be a role for radiotherapy in some extenuating circumstances, such as in immunosuppressed patients, and possibly as palliative care, but that the data are not strong enough to support a recommendation either way.
Related to this article








